Having had the opportunity to look at this device in detail, I always wondered who was willing to invest in this product, and who would want this product implanted in them? Maybe my later observation is based on the fact that I have never had back problems. The question that needs to be answered is; whom are these investors listening to when they are making their decisions to infuse an incredible amount of capital into a potential emerging technology? A surgeon who had hit a grand slam with a previous product? What ever happened to the X-Stop? A medical device consultant? A certified financial analyst? I know that there are no guarantees, it's a crap shoot! Yet, as investors become conservative from The Spine Industries Roadkill Tour of '09, will they have learned their lessons when it comes to investing in "fools gold!" As it stands, there still are investors willing to take a calculated risk, but the trend seems to be going away from hardware ventures. I would suspect if surgeons resect enough of the structural elements (tricomplex) of the spine and replace them with hardware, they should eliminate pain.
In today's market the average financial outlay for a 450 patient IDE is an estimated $15-18 million dollars, and that's not including associated training cost. So what happened to the other $50 million dollars? Based on what we learned from some of the other meltdowns, it probably resulted in nice offices, beautiful artwork, marketing expenditures, sculptures in the lobby, and senior management paying themselves an incredible salary, smoking Cohiba's, and drinking Cristal, all on pre-revenue dollars! If some of these investors would see the way their money is being managed, they would probably pull the plug themselves on their investments.
So as we wind down The Spine Industries Roadkill Tour of '09 here is our list of headliners:
- INNOVATIVE SPINE TECHNOLOGIES
Who will be next? Will it be an Impliant, Facet Solutions, Disc Motion Technologies, Hydrocision, Life Spine, U.S. Spine, Custom Spine? The word on the street is that some of these companies are hemorrhagging cash, and some are using unscrupulous methods to deleverage themselves. Recently, we heard from former employees from some of these companies, informing us that they have terminated distributors and replaced them with scrub technicians and cut commissions. Others are using their consulting surgeons/medical advisors as public relations spokesperson's to generate interest from private equity or investment banking. Do these investors understand that there is a conflict of interest when your medical advisor is the person selling the snakeoil? The problem that we see with our industry, is that many of these companies don't know how to manage themselves and their money conservatively. I am sure Mr. Fitzsimmons is a nice person, unfortunately, he wasn't that good at managing the money. Hopefully, he will be able to sell the product in an auction or fire sale for at least $15 million and repay some of his investors. The Spine Blogger wants to know what its readers think?